Trial · NCT05020782
The BeLimumab Antiphospholipid Syndrome Trial (BLAST)
NCT05020782, Phase 2, Phase 3, Unknown, University of Turin, Italy
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The BeLimumab Antiphospholipid Syndrome Trial (BLAST). Trials, record NCT05020782. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05020782
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The BeLimumab Antiphospholipid Syndrome Trial (BLAST)
- NCT number
- NCT05020782
- Status
- Unknown
- Phases
- Phase 2, Phase 3
- Enrollment
- 15 participants, estimated
- Lead sponsor
- University of Turin, Italy
- Conditions
- Antiphospholipid Syndrome
- Interventions
- Belimumab
- First posted
- 2021-08-25
- Last updated
- 2023-01-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Experiencing Adverse Events | 104 weeks | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 |
| Secondary | The Efficacy of Belimumab-thrombocytopenia | 104 weeks | Outcome measures scored as complete response (CR), partial (PR), and none (NR) at 24, 52, 104 weeks. For thrombocytopenia, CR defined as a platelet count of ≥150×109/μl,PR as 100-149,and NR as \<100. |
| Secondary | The Efficacy of Belimumab-CVD | 104 weeks | Outcome measures scored as complete response (CR), partial (PR), and none (NR) at 24, 52, 104 weeks.For CVD,CR defined as the disappearance of cardiac lesions, PR as 50%improvement,and NR as no change. |
| Secondary | The Efficacy of Belimumab-renal involvement | 104 weeks | Outcome measures scored as complete response (CR), partial (PR), and none (NR) at 24, 52, 104 weeks. For aPL nephropathy, CR defined as a normal serum creatinine level, inactive urinary sediment, and urinary protein: creatinine 0.5;PR as a serum cr level 15% above baseline, RBCs per high-power field 50% above baseline with no casts, 50%improvement in the urinary prt:cr, and estimated GFR 10%above baseline; and NR as the absence of C/PR. |
| Secondary | The Efficacy of Belimumab-cognitive impairment | 104 weeks | Outcome measures scored as complete response (CR), partial (PR), and none (NR) at 24, 52, 104 weeks. For cognitive dysfunction,CR defined as normalization of the cognitive impairment index with 50%improvement,PR as abnormal index with 50%, and NR as no change. |
| Secondary | The Efficacy of Belimumab-thrombosis | 104 weeks | Rate of documented thrombotic events |
| Secondary | Change in aPL profile | 104 weeks | Change in aPL levels at 24, 52, 104 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05020782
GET https://conductscience.org/api/trials/v1/NCT05020782/registered